Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Explore this paper's citation graph
Summary
Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive and should be preferred for first-step antihypertensive therapy.
- Type
- article
- Published
- 2002-12-18
- Cited by
- 5,373
- References
- 62
- OpenAlex
- https://openalex.org/W2562329777
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:26226052
Keywords
Medicine, Diuretic, Calcium channel blocker, Randomized controlled trial, Angiotensin-converting enzyme
References
- Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view.
- Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration.
- Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
- Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
- Treatment of Hypertension: A Clinical Epidemiologist's View
- Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.
- Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators.
- Trends in pharmacologic management of hypertension in the United States.
- Discrete sequential boundaries for clinical trials
- Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
- Upper bounds for type I and type II error rates in conditional power calculations
- Antihypertensive therapy: taking lipids into consideration.
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
- Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial
- Differences between blood-pressure-lowering drugs.
- A Multiple Comparison Procedure for Comparing Several Treatments with a Control
- Pathophysiology and treatment implications of hypertension in the African-American population.
- Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
- Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study.
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Cited by
- Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating nonregulator.
- 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
- Hidroclorotiazida x clortalidona: os diuréticos tiazídicos são todos iguais? Hydrochlorothiazide vs. chlorthalidone: all thiazides are the same?
- Aktuelle Therapie der Hypertonie bei Diabetes
- Anti-hypertensive drugs in children and adolescents.
- ACE Inhibition in Hypertension
- Perindopril versus Angiotensin II Receptor Blockade in Hypertension and Coronary Artery Disease
- Antihypertensive medication class and pulse pressure in the elderly: analysis based on the third National Health and Nutrition Examination Survey.
- Old and new cardiovascular risk factors: from unresolved issues to new opportunities.
- Effects of different blood-pressure-lowering regimens on major cardiac events.
- Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan®/HCT)
- Evolving targets for risk reduction in diabetes
- Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients: The Quinapril Titration Interval Management Evaluation Trial
- The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin–angiotensin system in vivo
- Old antihypertensives and new diabetes
- Risk stratification for the prevention of cardiovascular complications of hypertension
- Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis.
- Assessment of cardiovascular risk and choice of antihypertensive therapy
- Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials
- Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan
Related papers
- The use of angiotensin-converting enzyme inhibitors in the treatment of heart failure in hospital practice.
- β Adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics
- Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine.
- Which anti-hypertensive to add to a beta-blocker: ACE inhibitor or diuretic?
- Ordering of the Serum Angiotensin-Converting Enzyme Test in Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy: An Avoidable but Common Error.
- Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
- An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis.
- Age-Related Underutilization of Angiotensin-Converting Enzyme Inhibitors in Older Hospitalized Heart Failure Patients